Paul Tudor Jones Autolus Therapeutics PLC Transaction History

Tudor Investment Corp Et Al

  • $26.8 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021
SELL
$5.32 - $7.37 $74,432 - $103,113
-13,991 Closed
0 $0
Q2 2021

Aug 16, 2021
BUY
$4.78 - $7.96 $66,876 - $111,368
13,991 New
13,991 $93,000
Q3 2020

Nov 16, 2020
SELL
$11.64 - $16.3 $308,611 - $432,161
-26,513 Closed
0 $0
Q2 2020

Aug 14, 2020
SELL
$5.38 - $16.14 $97,087 - $291,262
-18,046 Reduced 40.5%
26,513 $425,000
Q1 2020

May 15, 2020
BUY
$4.2 - $13.0 $187,147 - $579,267
44,559 New
44,559 $267,000

Others Institutions Holding AUTL

# of Institutions
104
Shares Held
163M
Call Options Held
2.8K
Put Options Held
13.4K
View Full List

About Autolus Therapeutics plc

AUTL Quotes by TradingView
  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $205M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email